XML 83 R40.htm IDEA: XBRL DOCUMENT v3.3.1.900
Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - AstraZeneca Agreements [Member] - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 12 Months Ended 30 Months Ended
Dec. 31, 2013
Jul. 30, 2013
Jun. 30, 2015
Dec. 31, 2013
Dec. 31, 2015
Dec. 31, 2015
U.S./RoW [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Expected upfront, non-contingent and time-based payments   $ 374.0        
Upfront, non-contingent and time-based payments received       $ 82.0   $ 312.0
Contingent payment   62.0        
Development and regulatory approval milestones   550.0        
Commercial sales milestone   325.0        
Shared development costs   233.0        
Additional consideration based on net sales description         Low 20% range  
U.S./RoW [Member] | Development Milestones [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Receipt of development milestone payment     $ 15.0      
China [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront, non-contingent and time-based payments received $ 16.2          
Contingent payment   20.0        
Development and regulatory approval milestones   161.0        
Commercial sales milestone   167.5        
Proceeds from upfront payments   $ 28.2